Adenosine receptors as therapeutic targets
Open accessThe DOI matches its Crossref record; 215 of the 215 references it cites were found in a registry or an index.
Abstract
Adenosine receptors are major targets of caffeine, the most commonly consumed drug in the world. There is growing evidence that they could also be promising therapeutic targets in a wide range of conditions, including cerebral and cardiac ischaemic diseases, sleep disorders, immune and inflammatory disorders and cancer. After more than three decades of medicinal chemistry research, a considerable number of selective agonists and antagonists of adenosine receptors have been discovered, and some have been clinically evaluated, although none has yet received regulatory approval. However, recent advances in the understanding of the roles of the various adenosine receptor subtypes, and in the development of selective and potent ligands, as discussed in this review, have brought the goal of therapeutic application of adenosine receptor modulators considerably closer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among these, A1 and A2A receptors are considered the principal targets mediating caffeine’s physiological effects.”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“A key mechanism underlying the interaction between caffeine and exercise is caffeine’s pharmacological action as a competitive adenosine receptor antagonist.”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“Instead, competitive blockade of A1 and A2A adenosine receptors is widely regarded as the central mechanism underlying caffeine’s physiological effects during both habitual intake and exercise (Figure 1) [28,29,30,31].”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“Within the range of plasma concentrations relevant to sports nutrition practice, typically micromolar levels achieved after low-to-moderate caffeine intake, caffeine’s primary mechanism of action is unlikely to involve phosphodiesterase (PDE) inhibition or direct intracellular Ca2+ release.”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“This effect modulates key physiological processes such as anti-inflammatory responses, angiogenesis, and vasodilation, as illustrated in Figure 2 (left panel) [52,66,67,68].”
From Comparison of Polynucleotide and Polydeoxyribonucleotide in Dermatology: Molecular Mechanisms and Clinical Perspectives (2025) · cites this paper as [68]
Citations
Cites
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Klotz, K.-N., & Linden, J. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01511-4 · Cited by 2,585
Self-citationCalker, D. V., Müller, M., & Hamprecht, B. (1979) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1979.tb05236.x · Cited by 1,371
Ohta, A., & Sitkovsky, M. (2001) · Nature · doi:10.1038/414916a · Cited by 1,334
Astrocytic Purinergic Signaling Coordinates Synaptic Networks
Pascual, O., Casper, K. B., Kubera, C., Zhang, J., Revilla-Sanchez, R., Sul, J.-Y., Takano, H., Moss, S. J., McCarthy, K., & Haydon, P. G. (2005) · Science · doi:10.1126/science.1116916 · Cited by 1,280
Adenosine: A Mediator of the Sleep-Inducing Effects of Prolonged Wakefulness
Porkka-Heiskanen, T., Strecker, R. E., Thakkar, M., Bjørkum, A. A., Greene, R. W., & McCarley, R. W. (1997) · Science · doi:10.1126/science.276.5316.1265 · Cited by 1,252
Subclasses of external adenosine receptors.
Londos, C., Cooper, D. M., & Wolff, J. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.5.2551 · Cited by 1,081
Extracellular metabolism of ATP and other nucleotides
Zimmermann, H. (2000) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s002100000309 · Cited by 990
Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor
Ledent, C., Vaugeois, J.-M., Schiffmann, S. N., Pedrazzini, T., Yacoubi, M. E., Vanderhaeghen, J.-J., Costentin, J., Heath, J. K., Vassart, G., & Parmentier, M. (1997) · Nature · doi:10.1038/41771 · Cited by 918
Adenosine: an endogenous regulator of innate immunity
Haskó, G. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.11.003 · Cited by 899
Research works printed but not linked: 1
- Ji, X. D. & Jacobson, K. A. [3H]-ZM241385 as a radioligand at recombinant human A2B adenosine receptors. Drug Des. Discov. 16, 217–226 (1999).
Cited by
Items 401–500 of 1,001
Potent and Orally Bioavailable 8-Bicyclo[2.2.2]octylxanthines as Adenosine A1 Receptor Antagonists
Kiesman, W. F., Zhao, J. X., Conlon, P. R., Dowling, J. E., Petter, R. C., Lutterodt, F., Jin, X., Smits, G. J., Fure, M., Jayaraj, A. A., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0605381 · Cited by 43
Gao, Z., Ye, K., Göblyös, A., IJzerman, A. P., & Jacobson, K. A. (2008) · BMC Pharmacology · doi:10.1186/1471-2210-8-20 · Cited by 46
“There is growing evidence that they could be promising therapeutic targets in a wide range of conditions [1-3].”
BackgroundSelf-citationCryo-EM structures of adenosine receptor A3AR bound to selective agonists
Cai, H., Guo, S., Xu, Y., Sun, J. Y., Li, J., Xia, Z., Jiang, Y., Xie, X., & Xu, H. E. (2024) · Nature Communications · doi:10.1038/s41467-024-47207-6 · Cited by 42
“The broad expression of adenosine receptors poses challenges in designing subtype-selective compounds 20,21 .”
Autoimmunity in CD73/Ecto-5′-Nucleotidase Deficient Mice Induces Renal Injury
Blume, C. A., Felix, A., Shushakova, N., Gueler, F., Falk, C. S., Haller, H. G., & Schrader, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037100 · Cited by 47
“Adenosine exerts its action via specific G-protein coupled receptor subtypes classified as A1, A2a, A2b and A3 [11] which are pharmacologically relevant due to availability of highly specific agonists and antagonists [12].”
BackgroundCharacterization of the dynamic events of GPCRs by automated computational simulations
Gutiérrez‐de‐Terán, H., Bello, X., & Rodriguez, D. J. (2013) · Biochemical Society Transactions · doi:10.1042/bst20120287 · Cited by 42
Sabbadin, D., Ciancetta, A., Deganutti, G., Cuzzolin, A., & Moro, S. (2015) · MedChemComm · doi:10.1039/c5md00016e · Cited by 42
Adenosine Augmentation Therapy
Boison, D. (2012) · Oxford University Press eBooks · doi:10.1093/med/9780199746545.003.0090 · Cited by 42
CD39-adenosinergic axis in renal pathophysiology and therapeutics
Kishore, B. K., Robson, S. C., & Dwyer, K. M. (2018) · Purinergic Signalling · doi:10.1007/s11302-017-9596-x · Cited by 42
McCullough, K. M., Daskalakis, N. P., Gafford, G. M., Morrison, F. G., & Ressler, K. J. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0190-y · Cited by 44
Understanding Ligand Binding Selectivity in a Prototypical GPCR Family
Mattedi, G., Deflorian, F., Mason, J. S., de Graaf, C., & Gervasio, F. L. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00298 · Cited by 42
Incidence and risk factors of medical complications during inpatient stroke rehabilitation.
Hung, J.-W., Tsay, T.-H., Chang, H., Leong, C., & Lau, Y.-C. (2005) · PubMed · Cited by 42
Unpredictable Chronic Stress Alters Adenosine Metabolism in Zebrafish Brain
Zimmermann, F. F., Altenhofen, S., Kist, L. W., Leite, C. E., Bogo, M. R., Cognato, G. D. P., & Bonan, C. D. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9270-7 · Cited by 45
Melman, A., Wang, B., Joshi, B. V., Gao, Z., de Castro, S., Heller, C. L., Kim, S., Jeong, L. S., & Jacobson, K. A. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.08.007 · Cited by 42
Self-citationLane, J. R., Herenbrink, C. K., van Westen, G. J. P., Spoorendonk, J. A., Hoffmann, C., & IJzerman, A. P. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.075937 · Cited by 41
“There is significant therapeutic potential for both selective antagonists and agonists of the A2A AR (Jacobson and Gao, 2006; Miyamoto et al., 2009).”
BackgroundDias, R. B., Rombo, D. M., Ribeiro, J. A., & Sebastião, A. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.09.016 · Cited by 43
Investigational A3adenosine receptor targeting agents
Koscsó, B., Csóka, B., Pacher, P., & Haskó, G. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.573785 · Cited by 42
“The pyridylquinazoline derivative VUF5574 (N-(2-methoxyphenyl)-N’-[2-(3-pyrindinyl)-4-quinazolinyl]-urea) (Figure 2B) and the triazoloquinazoline MRS1220 are also used as selective A3AR antagonists [13], both with selectivity only in humans.”
Conesa‐Buendía, F. M., Llamas‐Granda, P., Larranaga‐Vera, A., Wilder, T., Largo, R., Herrero‐Beaumont, G., Cronstein, B. N., & Mediero, A. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3665 · Cited by 43
“The levels of extracellular adenosine differ in each tissue and in response to different levels of stress and to the basal stimulation of the receptor by the endogenous variations of the agonist.((12)) Decreased adenosine levels, resulting from tenofovir-mediated inhibition of ATP release via pannexin-1, likely explai…”
BackgroundSaku, O., Saki, M., Kurokawa, M., Ikeda, K., Takizawa, T., & Uesaka, N. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.12.028 · Cited by 41
Escudero, C., Roberts, J. M., Myatt, L., & Feoktistov, I. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00134 · Cited by 48
“…microvascular endothelial cells (hPMEC) from preeclamptic pregnancies (2.7 vs. 0.6 μmol/L) are at least three times higher than in normal pregnancy (Escudero et al., 2008), making it likely that, in preeclampsia, all adenosine receptors are likely to be stimulated (Jacobson and Gao, 2006).”
BackgroundInfluentialSlee, D. H., Zhang, X., Moorjani, M., Lin, E., Lanier, M. C., Chen, Y., Rueter, J. K., Lechner, S. M., Markison, S., Malany, S., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm070623o · Cited by 41
Purinergic signaling in the lumen of a normal nephron and in remodeled PKD encapsulated cysts
Hovater, M. B., Olteanu, D. S., Welty, E. A., & Schwiebert, E. M. (2008) · Purinergic Signalling · doi:10.1007/s11302-008-9102-6 · Cited by 44
McDermott, S., Eppert, K., Notta, F., Isaac, M. B., Datti, A., Al‐awar, R., Wrana, J. L., Minden, M. D., & Dick, J. E. (2011) · Blood · doi:10.1182/blood-2011-01-330019 · Cited by 46
“Adenosine can signal through four cell-surface G-protein-coupled receptors or be rapidly metabolized by adenosine kinase (ADK).(36) Various derivatives of adenosine [e.”
BackgroundStructure–activity relationships of adenosines with heterocyclic N6-substituents
Ashton, T. D., Aumann, K. M., Baker, S. P., Schiesser, C. H., & Scammells, P. J. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.10.028 · Cited by 40
Signaling pathways underlying the antidepressant-like effect of inosine in mice
Gonçalves, F. M., Neis, V. B., Rieger, D. K., Lopes, M. W., Heinrich, I. A., Costa, A. P., Rodrigues, A. L. S., Kaster, M. P., & Leal, R. B. (2016) · Purinergic Signalling · doi:10.1007/s11302-016-9551-2 · Cited by 42
“Meanwhile, the activation of these receptors is able to modulate several signaling pathways related to neuroplasticity and cell survival such as MEK/ERK1/2, CaMKII, PKA, PI3K/Akt, and GSK3β [42, 43].”
Gomes, J. I., Farinha‐Ferreira, M., Rei, N., Gonçalves‐Ribeiro, J., Ribeiro, J. A., Sebastião, A. M., & Vaz, S. H. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105363 · Cited by 44
Post exposure administration of A1 adenosine receptor agonists attenuates noise-induced hearing loss
Wong, A. C. Y., Guo, C. X., Gupta, R., Housley, G. D., Thorne, P. R., & Vlajkovic, S. M. (2009) · Hearing Research · doi:10.1016/j.heares.2009.12.004 · Cited by 41
Kim, Y., de Castro, S., Gao, Z., IJzerman, A. P., & Jacobson, K. A. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801659w · Cited by 50
Self-citationAllosteric Modulation of Purine and Pyrimidine Receptors
Jacobson, K. A., Gao, Z., Göblyös, A., & IJzerman, A. P. (2011) · Advances in pharmacology · doi:10.1016/b978-0-12-385526-8.00007-2 · Cited by 39
“Many novel drug concepts have been proposed based on administration of selective AR agonists and antagonists (Jacobson & Gao, 2006).”
BackgroundSelf-citationWang, Y., Chen, Y., Xiang, C., Jiang, G.-W., Xu, Y., Yin, L.-M., Zhou, D., Liu, Y., & Yang, Y. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112635 · Cited by 40
Hybrids of Coumarin Derivatives as Potent and Multifunctional Bioactive Agents: A Review
Fotopoulos, I., & Hadjipavlou‐Litina, D. (2019) · Medicinal Chemistry · doi:10.2174/1573406415666190416121448 · Cited by 46
Tebano, M. T., Martire, A., Chiodi, V., Ferrante, A., & Popoli, P. (2010) · The Scientific World JOURNAL · doi:10.1100/tsw.2010.164 · Cited by 41
“Adenosine is an important neuromodulator that is produced in the extracellular space through two different mechanisms: (1) ectonucleotidase degradation of ATP released by neurons and astrocytes, and (2) intracellular production followed by extracellular transport[46].”
BackgroundNanomaterials as drug delivery agents for overcoming the blood-brain barrier: A comprehensive review
Kulkarni, M., Patel, K., Patel, A. K., Patel, S., Desai, J. L., Patel, M. M., Shah, U., Patel, A. D., & Solanki, N. D. (2023) · ADMET & DMPK · doi:10.5599/admet.2043 · Cited by 73
“Four sub-types of adenosine receptors known as G-protein-coupled receptors are recognised: A1, A2A, A2B, and A3 [76].”
BackgroundTicagrelor potentiates adenosine-induced stimulation of neutrophil chemotaxis and phagocytosis
Alsharif, K. F., Thomas, M. R., Judge, H. M., Khan, H. Z., Prince, L. R., Sabroe, I., Ridger, V. C., & Storey, R. F. (2015) · Vascular Pharmacology · doi:10.1016/j.vph.2015.02.006 · Cited by 40
“Four different adenosine receptors exist, which are activated at different concentrations of adenosine and expressed on a wide range of different cell types [23].”
BackgroundColotta, V., Catarzi, D., Varano, F., Lenzi, O., Filacchioni, G., Martini, C., Trincavelli, M. L., Ciampi, O., Traini, C., Pugliese, A. M., et al. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.04.039 · Cited by 42
Modulation of Innate Immunity by Adenosine Receptor Stimulation
Ramakers, B. P., Riksen, N. P., van der Hoeven, J. G., Smits, P., & Pickkers, P. (2011) · Shock · doi:10.1097/shk.0b013e318225aee4 · Cited by 50
“Not only does it vary between receptor subtypes, it also depends on the specific cell type involved (19).”
BackgroundAdenosine A2A receptor signaling regulation of cardiac NADPH oxidase activity
Ribé, D., Sawbridge, D., Thakur, S., Hussey, M. J., Ledent, C. A., Kitchen, I., Hourani, S. M. O., & Li, J. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.12.035 · Cited by 41
“The involvement of the A2AR in the regulation of cardiac ROS production was further supported by our experiments using wild-type mice treated with SCH58261, which is a highly selective A2AR antagonist [14,18].”
ResultKovács, Z., Juhász, G. D., Palkovits, M., Dobolyi, Á., & Kékesi, K. A. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611795347636 · Cited by 43
“Nucleoside receptors are not very specific, and they can bind several nucleosides, agonists as well as antagonists with different affinities [5, 27].”
BackgroundInfluentialIyer, S. V., Ranjan, A., Elias, H. K., Parrales, A., Sasaki, H., Roy, B. C., Umar, S., Tawfik, O. W., & Iwakuma, T. (2016) · Nature Communications · doi:10.1038/ncomms13561 · Cited by 39
Structure-Based Design of Potent and Selective Ligands at the Four Adenosine Receptors
Jespers, W., de Oliveira, A. L. N., Prieto‐Díaz, R., Majellaro, M., Åqvist, J., Sotelo, E., & Gutiérrez‐de‐Terán, H. (2017) · Molecules · doi:10.3390/molecules22111945 · Cited by 38
“The adenosine A1 receptor, which plays a significant role in the regulation of neural, renal an cardiac sys ems [3], was the fir t AR to be characterized [39].”
BackgroundMolecular dissection of the human A 3 adenosine receptor coupling with β-arrestin2
Storme, J., Cannaert, A., Craenenbroeck, K. V., & Stove, C. P. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.01.008 · Cited by 44
Truly Target-Focused Pharmacophore Modeling: A Novel Tool for Mapping Intermolecular Surfaces
Mortier, J., Dhakal, P., & Volkamer, A. (2018) · Molecules · doi:10.3390/molecules23081959 · Cited by 38
“Among them, adenosine receptors have become central therapeutic targets for the treatment of various pathologies (cardiovascular, renal, and nervous systems, as well as endocrine and pulmonary disorders) for more than a decade [61].”
BackgroundTherapeutic potential of adenosine kinase inhibition—Revisited
Jarvis, M. F. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.506 · Cited by 40
Hua, X., Erikson, C. J., Chason, K. D., Rosebrock, C. N., Deshpande, D. A., Penn, R. B., & Tilley, S. L. (2007) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00058.2007 · Cited by 38
“Therefore, adenosine receptors are attractive therapeutic targets for these diseases (21).”
BackgroundZhang, X., Tellew, J. E., Luo, Z., Moorjani, M., Lin, E., Lanier, M. C., Chen, Y., Williams, J. P., Saunders, J., Lechner, S. M., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800851u · Cited by 41
Multimodal drugs and their future for Alzheimer's and Parkinson's disease
der Schyf, C. J. V., & Geldenhuys, W. J. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-386467-3.00006-6 · Cited by 40
Adenosine signalling drives antidepressant actions of ketamine and ECT
Yue, C., Wang, N., Zhai, H., Yuan, Z., Cui, Y., Jing, Q., Zhou, Y., Fan, X., Wang, H., Wu, Z., et al. (2025) · Nature · doi:10.1038/s41586-025-09755-9 · Cited by 55
“This level is sufficient to engage A 1 and A 2A receptors but remains substantially below the activation threshold for A 2B and A 3 receptors 24,28,29 .”
InfluentialLiang, D., Zuo, A., Shao, H., Chen, M., Kaplan, H. J., & Sun, D. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401959 · Cited by 40
Minutoli, L., Arena, S., Bonvissuto, G., Bitto, A., Polito, F., Irrera, N., Arena, F., Fragalà, E., Romeo, C., Nicòtina, P. A., et al. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.07.1047 · Cited by 42
“Adenosine, which is known to be released in hypoxic tissues, may represent a therapeutic target (12); indeed, activation of adenosine A2A-receptors stimulates VEGF release (13).”
BackgroundPitaksalee, R., Sanvarinda, Y., Sinchai, T., Sanvarinda, P., Thampithak, A., Jantaratnotai, N., Jariyawat, S., Tuchinda, P., Govitrapong, P., & Sanvarinda, P. (2015) · Neurotoxicity Research · doi:10.1007/s12640-014-9513-9 · Cited by 41
Deflorian, F., Kumar, T. S., Phan, K., Gao, Z., Xu, F., Wu, H., Katritch, V., Stevens, R. C., & Jacobson, K. A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201461q · Cited by 37
Self-citationRegulation of protein kinase C-epsilon and its age-dependence
Chen, K., Qin, J., Osei, W., & Hu, K. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.12.012 · Cited by 42
Shukla, M., Roy, K., Kaur, C., Nayak, D., Mani, K. V., Shukla, S., & Kapoor, N. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.02.006 · Cited by 36
A Supervised Molecular Dynamics Approach to Unbiased Ligand–Protein Unbinding
Deganutti, G., Moro, S., & Reynolds, C. A. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b01094 · Cited by 37
“The adenosine A 1 receptor (A 1 R) is involved in ischemic disorders 79 and in the nociceptive transmission 84 .”
BackgroundThe regulation of CD73 in non-small cell lung cancer
Han, Y., Lee, T., He, Y., Raman, R., Irizarry, A., Martín, M. L., & Giaccone, G. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.04.025 · Cited by 42
Cardioprotective mechanisms activated in response to myocardial ischemia.
Liu, S. Q., Tefft, B. J., Zhang, D., Roberts, D., Schuster, D. J., & Wu, A. (2011) · PubMed · Cited by 39
1,3,7-Triethyl-substituted xanthines—possess nanomolar affinity for the adenosine A1 receptor
der Walt, M. M. V., & Terre’Blanche, G. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.09.012 · Cited by 37
Urmaliya, V., Church, J. E., Coupar, I. M., Rose’Meyer, R. B., Pouton, C. W., & White, P. J. (2009) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181a443e2 · Cited by 37
“794; 18,600; and 72 nM at A2A, A2B, or A3 adenosine receptors, respectively).(40) In addition to necrotic cell death, we also measured apoptotic cell death.”
BackgroundMolecular modeling of adenosine receptors: new results and trends
Martinelli, A., & Tuccinardi, T. (2007) · Medicinal Research Reviews · doi:10.1002/med.20106 · Cited by 41
Rickles, R. J., Pierce, L. T., Giordano, T. P., Tam, W. F., McMillin, D. W., Delmore, J. E., Laubach, J. P., Borisy, A. A., Richardson, P. G. G., & Lee, M. S. (2010) · Blood · doi:10.1182/blood-2009-11-252668 · Cited by 41
Highlights on the Development of A2A Adenosine Receptor Agonists and Antagonists
Cristalli, G., Cacciari, B., Ben, D. D., Lambertucci, C., Moro, S., Spalluto, G., & Volpini, R. (2006) · ChemMedChem · doi:10.1002/cmdc.200600193 · Cited by 41
Reduced Sleep and Low Adenosinergic Sensitivity in Cacna1a R192Q Mutant Mice
Deboer, T., van Diepen, H. C., Ferrari, M. D., van den Maagdenberg, A. M. J. M., & Meijer, J. H. (2012) · SLEEP · doi:10.5665/sleep.2316 · Cited by 38
Ellermann, M., Paulini, R., Jakob‐Roetne, R., Lerner, C., Borroni, E., Roth, D., Ehler, A., Schweizer, W. B., Schlatter, D., Rudolph, M. G., et al. (2011) · Chemistry - A European Journal · doi:10.1002/chem.201003648 · Cited by 43
Mitani, T., Watanabe, S., Yoshioka, Y., Katayama, S., Nakamura, S., & Ashida, H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.09.017 · Cited by 43
“ARs exist as four subtypes, AR1, AR2a, AR2b and AR3, and agonist-bound ARs regulate adenylyl cyclase activity, resulting in increased or decreased cAMP synthesis from ATP [14].”
BackgroundComeo, E., Kindon, N. D., Soave, M., Stoddart, L. A., Kilpatrick, L. E., Scammells, P. J., Hill, S. J., & Kellam, B. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01856 · Cited by 46
Reinhart, P. H., Kaltenbach, L. S., Essrich, C., Dunn, D., Eudailey, J., DeMarco, C. T., Turmel, G. J., Whaley, J. C., Wood, A., Cho, S., et al. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.03.017 · Cited by 39
Kan, Y., Okabayashi, T., Yokota, S., Yamamoto, S., Fujii, N., & Yamashita, T. (2012) · Journal of Virology · doi:10.1128/jvi.01196-12 · Cited by 40
“Conversely, adenosine receptor A2A and A2B transduce positive signals, which stimulate cAMP formation (7, 11).”
BackgroundGreer, S., Page, C. W., Joshi, T., Yan, D., Newton, R., & Giembycz, M. A. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.206284 · Cited by 37
“The adenosine A2B-receptor can couple tomultiple effectors including adenylyl cyclase and phospholipase Cb (Jacobson and Gao, 2006).”
BackgroundMapping the allosteric sites of the A2A adenosine receptor
Caliman, A. D., Miao, Y., & McCammon, J. A. (2017) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13053 · Cited by 38
Purinergic signaling: Diverse effects and therapeutic potential in cancer
Kaur, J., & Dora, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1058371 · Cited by 37
Characterization of new G protein-coupled adenine receptors in mouse and hamster
Thimm, D., Knospe, M., Abdelrahman, A., Moutinho, M., Alsdorf, B. B. A., von Kügelgen, I., Schiedel, A. C., & Müller, C. E. (2013) · Purinergic Signalling · doi:10.1007/s11302-013-9360-9 · Cited by 35
Noise-induced cochlear inflammation
Tan, W. J. T. (2013) · World Journal of Otorhinolaryngology · doi:10.5319/wjo.v3.i3.89 · Cited by 34
Jacobson, K. A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400422s · Cited by 36
Self-citationYang, T., Zollbrecht, C., Winerdal, M. E., Zhuge, Z., Zhang, X., Terrando, N., Checa, A., Sällström, J., Wheelock, C. E., Winqvist, O., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003868 · Cited by 35
Yu, J., Ahn, S.-Y., Kim, H. J., Lee, M. Y., Ahn, S., Kim, J., Jin, S. H., Lee, E., Kim, G., Cheong, J. H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00805 · Cited by 35
Self-citationCuzzolin, A., Deganutti, G., Salmaso, V., Sturlese, M., & Moro, S. (2017) · ChemMedChem · doi:10.1002/cmdc.201700564 · Cited by 35
Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension
Alencar, A. K. N., Montes, G. C., Barreiro, E. J., Sudo, R. T., & Zapata‐Sudo, G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00858 · Cited by 38
“…of targeting ARs as a therapeutic approach in various clinical conditions, including cerebral and cardiac diseases, sleep disorders, immune and inflammatory disorders, and cancer (Jacobson and Gao, 2006; Hasko et al., 2008; McIntosh and Lasley, 2012; Chen et al., 2013; Headrick et al., 2013).”
BackgroundThuraiaiyah, J., Kokoti, L., Al‐Karagholi, M. A., & Ashina, M. (2022) · The Journal of Headache and Pain · doi:10.1186/s10194-022-01412-0 · Cited by 37
“Adenosine receptors activate the mitogen-activated protein kinase (MAPK), leading to survival, cell growth, and differentiation [20], and modulate the activity of adenylate cyclase [11, 20], the enzyme that regulates intracellular concentration of cyclic adenosine monophosphate (cAMP) [38].”
BackgroundInfluentialYan, X., Zhang, Z., Yao, H., Guan, Y., Zhu, J., Zhang, L., Jia, Y.-L., & Wang, R. (2012) · Phytotherapy Research · doi:10.1002/ptr.4899 · Cited by 36
Afferent mechanisms of sodium retention in cirrhosis and hepatorenal syndrome
Oliver, J. A., & Verna, E. C. (2010) · Kidney International · doi:10.1038/ki.2010.4 · Cited by 35
Adenosine amine congener mitigates noise-induced cochlear injury
Vlajkovic, S. M., Lee, K., Wong, A. C. Y., Guo, C. X., Gupta, R., Housley, G. D., & Thorne, P. R. (2010) · Purinergic Signalling · doi:10.1007/s11302-010-9188-5 · Cited by 35
“Adenosine receptor agonists were successfully used in the treatment of ischemic brain and cardiac injury [8, 9], demonstrating an extraordinary cytoprotective function.”
BackgroundMethodNovel approaches to antiplatelet therapy
Gresele, P., & Momi, S. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115297 · Cited by 36
The role of activated adenosine receptors in degranulation of human LAD2 mast cells
Leung, C. T., Li, A., Banerjee, J., Gao, Z., Kambayashi, T., Jacobson, K. A., & Civan, M. M. (2014) · Purinergic Signalling · doi:10.1007/s11302-014-9409-4 · Cited by 38
Self-citationAdenosine A2A receptor dynamics studied with the novel fluorescent agonist Alexa488-APEC
Brand, F. J., Klutz, A. M., Jacobson, K. A., Fredholm, B. B., & Schulte, G. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.05.036 · Cited by 43
Self-citationModulation of neuroimmunity by adenosine and its receptors: Metabolism to mental illness
Chiu, G. S., & Freund, G. G. (2014) · Metabolism · doi:10.1016/j.metabol.2014.09.003 · Cited by 41
“Use of A2A AR antagonists in the clinical treatment of Parkinson’s disease [74] opens the door for the critical evaluation of receptor-specific adenosine interactions and the key action of adenosine as a metabolite that regulates mental processes [109].”
BackgroundPredicted structures of agonist and antagonist bound complexes of adenosine A3 receptor
Kim, S., Riley, L., Abrol, R., Jacobson, K. A., & Goddard, W. A. (2011) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.23012 · Cited by 33
“To rapidly identify the best 1000 of these, we first consider each helix interacting with just one other helix, leading to 12 3 12 5 144 combinations for each of the 12 pairs of interacting helices (1-2, 2-4, 4-5, 5-6, 6-7, 1-7, 1-3, 2-3, 3-4, 3-5, 3-6, 37).”
BackgroundSelf-citationLocal delivery of adenosine receptor agonists to promote bone regeneration and defect healing
Lopez, C. D., Bekisz, J. M., Corciulo, C., Mediero, A., Coelho, P. G., Witek, L., Flores, R. L., & Cronstein, B. N. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.010 · Cited by 34
Coppi, E., Cherchi, F., Lucarini, E., Ghelardini, C., Pedata, F., Jacobson, K. A., Mannelli, L. D. C., Pugliese, A. M., & Salvemini, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157952 · Cited by 36
Self-citationChaudhari, D., Katari, O., Ghadi, R., Kuche, K., Date, T., Bhargavi, N., & Jain, S. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c00594 · Cited by 34
Multi-Objective Evolutionary Design of Adenosine Receptor Ligands
van der Horst, E., Marqués‐Gallego, P., Mulder‐Krieger, T., van Veldhoven, J., Kruisselbrink, J. W., Aleman, A., Emmerich, M., Brussee, J., Bender, A., & IJzerman, A. P. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci2005115 · Cited by 34
Volpini, R., Buccioni, M., Ben, D. D., Lambertucci, C., Lammi, C., Marucci, G., Ramadori, A. T., Klotz, K., & Cristalli, G. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900754g · Cited by 41
Allosteric modulation of adenosine receptors
Göblyös, A., & IJzerman, A. P. (2008) · Purinergic Signalling · doi:10.1007/s11302-008-9105-3 · Cited by 34
“As adenosine receptors were among the first GPCRs found to be allosterically regulated, these receptors have often been reviewed also [6–8].”
Ye, Y., Saïd, G., Lin, Y., Manickavasagam, S., Hughes, M. G., McAdoo, D. J., Perez‐Polo, R. J., & Birnbaum, Y. (2008) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-008-6105-z · Cited by 34
“With average daily intake of 3.1 cups of coffee/day, the daily consumption of caffeine may reach 4 mg/kg, a dose that is sufficient to block the ARs [37].”
BackgroundInfluentialNucleoside Map of the Human Central Nervous System
Kovács, Z., Dobolyi, Á., Juhász, G. D., & Kékesi, K. A. (2009) · Neurochemical Research · doi:10.1007/s11064-009-0080-z · Cited by 37
“This finding warrants an increasing attention to the understanding of the roles of nucleosides in the CNS [3, 7, 13, 82].”
BackgroundBench-to-bedside review: Adenosine receptors – promising targets in acute lung injury?
Schepp, C. P., & Reutershan, J. (2008) · Critical Care · doi:10.1186/cc6990 · Cited by 34
“Aside from its numerous effects on the central nervous system, A1 signaling plays a pivotal role in manifesting I/R injury in various tissues [38,39].”
Chen, M., Liang, D., Zuo, A., Shao, H., Kaplan, H. J., & Sun, D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132348 · Cited by 37
“Increased adenosine levels in the extracellular space are reported to decreased inflammationinduced tissue damage and injury [27,28], but high adenosine generation is also reported to undermine immune responses and enhance tissue damage [29,30].”
BackgroundKhanapur, S., Paul, S., Shah, A. D., Vatakuti, S., Koole, M. J. B., Zijlma, R., Dierckx, R., Luurtsema, G., Garg, P., van Waarde, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500700y · Cited by 34
Azoloazines as A2areceptor antagonists. Structure – activity relationship
Savateev, K. V., Ulomsky, E. N., Butorin, I. I., Чарушин, В. Н., Русинов, В. Л., & Чупахин, О. Н. (2018) · Russian Chemical Reviews · doi:10.1070/rcr4792 · Cited by 34
Structure-kinetics relationships of Capadenoson derivatives as adenosine A 1 receptor agonists
Louvel, J., Guo, D. M., Soethoudt, M., Mocking, T. A. M., Lenselink, E. B., Mulder‐Krieger, T., Heitman, L. H., & IJzerman, A. P. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.07.023 · Cited by 34
McKenna, W. L., Wong‐Staal, C., Kim, G. C., Macias, H., Hinck, L., & Bartoe, J. L. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05040.x · Cited by 35
Morizzo, E., Capelli, F., Lenzi, O., Catarzi, D., Varano, F., Filacchioni, G., Vincenzi, F., Varani, K., Borea, P. A., Colotta, V., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070852a · Cited by 34
Metadata
- Authors
- Jacobson, K. A., & Gao, Z.-G.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Jacobson, Kenneth A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-03
- Volume
- 5
- Issue
- 3
- Pages
- 247-264
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC3463109
- OpenAlex
- W1985598247
- Cited by
- 1,431
- References
- 215
- Citations by year
- 2026: 34 · 2025: 50 · 2024: 52 · 2023: 55 · 2022: 80 · 2021: 58 · 2020: 65 · 2019: 79 · 2018: 66 · 2017: 59 · 2016: 65 · 2015: 64 · 2014: 80 · 2013: 80 · 2012: 83
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (Z01DK031117)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- adenosine receptors, adenosine receptor agonists, adenosine receptor antagonists, selective ligands, caffeine, cardiovascular disease, ischemic diseases, sleep disorders, inflammatory diseases, cancer, neurological disorders, drug development
- MeSH terms
- Animals, Disease, Drug Therapy, Humans, Ligands, Structure-Activity Relationship, Molecular Structure, Signal Transduction, Receptors, Purinergic P1, Purinergic P1 Receptor Agonists, Purinergic P1 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.